Thrombocytopenia-associated Multiple Organ Failure: What Is It? Understanding Pathological Coagulation and Systemic Endotheliopathy Bench-to-bedside Review: Thrombocytopenia-associated Multiple Organ Failure – a Newly Appreciated Syndrome in the Critically Ill

[1]  J. le Gall,et al.  Time course of organ dysfunction in thrombotic microangiopathy patients receiving either plasma perfusion or plasma exchange* , 2006, Critical care medicine.

[2]  A. Chauhan,et al.  Systemic antithrombotic effects of ADAMTS13 , 2006, The Journal of experimental medicine.

[3]  T. Ohmori,et al.  Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. , 2006, Blood.

[4]  A. Chauhan,et al.  The Metalloprotease ADAMTS13 Is a Natural Anti-Thrombotic. , 2005 .

[5]  A. Chauhan,et al.  Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. , 2005, The Journal of clinical investigation.

[6]  D. Motto,et al.  Additional Environmental and/or Genetic Factors Are Required to Trigger TTP in ADAMTS13-Deficient Mice. , 2004 .

[7]  D. Motto.  ADAMTS-13, VWF, inflammation, and thrombosis , 2004 .

[8]  L. Berggren,et al.  Plasma exchange as rescue therapy in multiple organ failure including acute renal failure. , 2003, Critical care medicine.

[9]  R. Busund,et al.  Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial , 2002, Intensive Care Medicine.

[10]  J. Vincent,et al.  Time course of platelet counts in critically ill patients , 2002, Critical care medicine.

[11]  J. Reeves.  A Review of Plasma Exchange in Sepsis , 2002, Blood Purification.

[12]  J. Carcillo,et al.  The Tissue Factor and Plasminogen Activator Inhibitor Type-1 Response in Pediatric Sepsis-induced Multiple Organ Failure , 2002, Thrombosis and Haemostasis.

[13]  T. Foroud,et al.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura , 2001, Nature.

[14]  A. Houllier,et al.  Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. , 2001, Blood.

[15]  J. Kelton,et al.  Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. , 2001, Blood.

[16]  Y. Han,et al.  Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target? , 2001, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[17]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[18]  S. Grosso,et al.  Whole blood transfusion for exsanguinating coagulopathy in a US field surgical hospital in postwar Kosovo. , 2000, The Journal of trauma.

[19]  V. Pettilä,et al.  Protein C substitution in sepsis-associated purpura fulminans , 2000, Critical care medicine.

[20]  A. Wilmer,et al.  Thrombocytopenia and prognosis in intensive care , 2000, Critical care medicine.

[21]  P. V. van Genderen,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY von Willebrand Factor Propeptide in Vascular Disorders: A Tool to Distinguish Between Acute and Chronic Endothelial Cell Perturbation , 1999 .

[22]  A. Flahault,et al.  Thrombocytopenia in a surgical ICU. , 1999, Chest.

[23]  H. Tsai,et al.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. , 1998, The New England journal of medicine.

[24]  B. Lämmle,et al.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. , 1998, The New England journal of medicine.

[25]  C. Harrison,et al.  Plasma exchange with solvent/detergent‐treated plasma of resistant thrombotic thrombocytopenic purpura , 1996, British journal of haematology.

[26]  D. Sutton,et al.  Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura , 1996, British journal of haematology.

[27]  P. Lester,et al.  Hemolytic-uremic syndrome without evidence of microangiopathic hemolytic anemia on peripheral blood smear. , 1996, Southern medical journal.

[28]  F Doyon,et al.  Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. , 1995, JAMA.

[29]  François Gouin,et al.  Incidence, Risk Factors, and Outcome of Severe Sepsis and Septic Shock in Adults: A Multicenter Prospective Study in Intensive Care Units , 1995 .

[30]  S. Fava,et al.  Thrombotic thrombocytopenic purpura‐like syndrome in the absence of schistocytes , 1995, British journal of haematology.

[31]  R. Baughman,et al.  Thrombocytopenia in the intensive care unit. , 1993, Chest.

[32]  C. Chopin,et al.  Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. , 1993, Chest.

[33]  K. P. Hui,et al.  Thrombocytopenia in sepsis: a predictor of mortality in the intensive care unit. , 1993, Singapore medical journal.

[34]  M. McManus,et al.  Coagulopathy as a predictor of outcome in meningococcal sepsis and the systemic inflammatory response syndrome with purpura , 1993, Critical care medicine.

[35]  W. Bell,et al.  Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. , 1991, The New England journal of medicine.

[36]  J. Kelton,et al.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. , 1991, The New England journal of medicine.

[37]  Michael F. Wilson,et al.  Impact of encephalopathy on mortality in the sepsis syndrome. The Veterans Administration Systemic Sepsis Cooperative Study Group. , 1990, Critical care medicine.

[38]  H. Kwaan.  Miscellaneous secondary thrombotic microangiopathy. , 1987, Seminars in hematology.

[39]  H. Kwaan.  Introduction: Thrombotic microangiopathy , 1987 .

[40]  Y. Asada,et al.  Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. , 1985, Thrombosis research.

[41]  P. Hattersley,et al.  Cryoprecipitates as a Source of Fibrinogen in Treatment of Disseminated Introvascular Coagulation (DIC) , 1976, Transfusion.

[42]  Y. Fujimura.  [Thrombotic microangiopathy]. , 2006, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[43]  B. Jude,et al.  Protein C and S deficiency in severe infectious purpura of children: A collaborative study of 40 cases , 2005, Intensive Care Medicine.

[44]  G. Rock,et al.  Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. , 2001, Clinical laboratory.

[45]  H. Riess,et al.  Treatment Options for Clinically Recognized Disseminated Intravascular Coagulation , 1998, Seminars in thrombosis and hemostasis.

[46]  F. Cohen,et al.  Biochemistry and genetics of von Willebrand factor. , 1998, Annual review of biochemistry.

[47]  M. Levin,et al.  Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. , 1998, Critical care medicine.

[48]  R. Bick.  Disseminated Intravascular Coagulation: Pathophysiological Mechanisms and Manifestations , 1998, Seminars in thrombosis and hemostasis.

[49]  R. Bick.  Disseminated Intravascular Coagulation: Objective Clinical and Laboratory Diagnosis, Treatment, and Assessment of Therapeutic Response , 1996, Seminars in thrombosis and hemostasis.

[50]  A. Nicolini,et al.  Iloprost in the treatment of thrombotic microangiopathy: report of thirteen cases. , 1996, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[51]  M. Dreyfus,et al.  Replacement Therapy with a Monoclonal Antibody Purified Protein C Concentrate in Newborns with Severe Congenital Protein C Deficiency , 1995, Seminars in thrombosis and hemostasis.

[52]  M. McManus,et al.  Intensive blood and plasma exchange for treatment of coagulopathy in meningococcemia , 1995, Journal of clinical apheresis.

[53]  J. Kelton,et al.  Comparison of Plasma Exchange With Plasma Infusion in the Treatment of Thrombotic Thrombocytopenia Purpura , 1992 .

[54]  J. Holland,et al.  Management of leukaemia-associated disseminated intravascular coagulation (DIC). , 1982, Haematologia.